1.Maher E, Kaelin WG. 1997 von Hippel-Lindau disease. Medicine 76:381-391
2.Friedrich CA. 2001 Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Gen 10 (7):763-767
3.Lonser RR, Glenn GM, Walther MM, Chew EY, Libutti SK, Linehan WM, Oldfield EH. 2003 von Hippel-Lindau disease. Lancet 361:2059-2067
4.Linehan WM & Klausner RD. Renal carcinoma. In: Vogelstein B (ed.). The genetic basis of human cancer. 1998
5.Neumann, H.P. & O.D. Wiestler. 1991 Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337: 1052-1054
6.Zbar B., T. Kishida, F. Chen, et al. 1996 Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8: 348-57.
7.Filling-Katz MR, Choyke PL, Oldfield E, et al. 1991 Central nervous system involvement in von Hippel-Lindau disease. Neurology 41:41-46
8.Neumann HP, Eggert H, Weigel K, et al. 1989 Hemangioblastomas of the central nervous system: a ten year study with spezial reference to von Hippel-Lindau syndrome. J Neurosurg 70:24-30
9.Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. 2003 The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98:82-94
10.Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, Oldfield EH. 2004 Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 55:721-728
11.Schmid D, Natt E, Neumann HP. 2000 Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res 5:47-58
12.Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. 1996 Allelic deletion of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089-2094
13.Neumann HP, Riegler P, Huber W, et al. 2001 The challenge of kidney lesions in von Hippel-Lindau disease. Contrib Nephrol 136:193-207
14.Richard S., D. Chaveau, Y. Chretien et al. 1994 Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol 23: 1-27.
15.Grubb RL, Choyke PL, Pinto PA, Linehan WM, Walther MM. 2005 Management of von Hippel-Lindau associated kidney cancer. Nat Clin Pract Urol 2:248-255
16.Kaelin WG Jr. 2004 The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S-5S
17.Linehan WM, Vaselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. 2004 Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10:6282S-9S
18.Choyke PL, Glenn GM, Walther MM, et al. 1995 Von Hippel-Lindau disease: genetic, clinical and imaging features. Radiology 194:629-636
19.Poston CD, Jaffe GS, Lubensky IA, et al. 1995 Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153:22-30
20.Jamis-Dow CA, Choyke PL, Jennings SB, et al. 1996 Small (<3 cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 198:785-790
21.Walther MM, Choyke PL, Weiss G, et al. 1995 Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153:913-916
22.Choyke PL, Glenn G, Walther MM, et al. 1992 The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR 159:1229-1234
23.Neumann HP, Bender BU, Berger DP, et al. 1998 Prevalence, morphology, and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 160:1248-1254
24.Chretien Y, Chauveau D, Richard S, Droz D, Correas JM, et al. 1997 Treatment of von Hippel-Lindau disease with renal involvement. Prog Urol 7:939-947
25.Walther M.M., R. Reiter, H.R. Keiser et al. 1999. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162: 659-664.
26.Neumann H.P., D.P. Berger, G. Sigmund et al. 1993 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329: 1531-1538
27.Sato Y, Waziri M, Smith W, Frey E: Hippel-Lindau disease: MR imaging. Radiology 1988;166:241-246
28.Atuk NO, McDonald T, Wood T, Carpenter JT, Walzak MP, Donaldson M, Gillenwater JY: Familial pheochromocytoma, hypercalcemia, and von Hippel-Lindau disease. A ten year study of a large family. Medicine (Baltimore) 1979; 58:208
29.Walther M.M., Herring J., Enquist E., et al. 1999 Von Recklinghausen’s disease and pheochromocytomas. J Urol 162, 1582-1586
30.Pacak K., G.P. Chrousos., C.A. Koch. 2001. Pheochromocytoma: progress in diagnosis, therapy, and genetics. In Adrenal Disorders. A. Margioris & G.P. Chrousos, Eds.: 379-413. Humana Press. New York, NY.
31.Koch, C.A., D. Mauro, M.M. Walther et al. 2002 Pheochromocytomas in VHL disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocrine Pathol 13(1):17-27
32.Koch CA, Vortmeyer AO, Diallo R, et al. 2002 Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 146:381-388
33.Eisenhofer G, Lenders JW, Linehan WM, et al. 1999 Plasma normetanephrine and metanephrine for detecting pheochromocytomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879
34.Lenders JWM, Pacak K, Walther MM, et al. 2002 Biochemical diagnosis of pheochromocytoma. Which is the best test ? JAMA 287:1427-1434
35.Hes FJ, Hoppener JW, Lips CJ. 2003 Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 88:969-974
36.Weise M, Merke DP, Pacak K, et al. 2002 Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 87:1955-1960
37.Pacak K, Linehan WM, Eisenhofer G, et al. 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329
38.Maher E.R., J.R.. Yates, R. Harries et al. 1990 Clinical features and natural history of von Hippel-Lindau disease. Quart J Med 77: 1151-63
39.Ritter M.M., A. Frilling, P.A. Crossey et al. 1996 Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 81: 1035-7
40.Eisenhofer G, Walther MM, Huynh TT, et al. 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 86:1999-2008
41.Neumann HP, Bausch B, McWhinney, et al. 2002 Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
42.Pavlovich CP, Linehan WM, Walther MM. 2001 Partial adrenalectomy in patients with multiple adrenal tumors. Curr Urol Rep 2:19-23
43.Walther MM, Keiser HR, Linehan WM. 1999 Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 17:35-39
44.Brunt LM, Lairmore TC, Doherty GM, et al. 2002 Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg 235:713-721
45.Neumann HP, Bender BU, Reincke M, et al. 1999 Adrenal sparing surgery for pheochromocytoma. Br J Surg 84:94-97
46.Choyke PL, Glenn GM, Wagner JP, et al. 1997 Epididymal cystadenomas in von Hippel-Lindau disease. Urology 49:926-931
47.Neumann HP, Dinkel E, Brambs H, et al. 1991 Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 101:465-471
48.Hough MT, Stephens DH, Johnson CD, Binkovitz LA. 1994 Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. Am J Roentgenol 162:1091-1094
49.Binkovitz LA, Johnson CD, Stephens DH. 1990 Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. Am J Roentgenol 155:501-505
50.Lubenksy IA, Pack SD, Ault D, et al. 1998 Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients. Am J Pathol 153:223-231
51.Libutti SK, Choyke PL, Bartlett DL, et al. 1998 Pancreatic neuroendocrine tumors associated with von Hippel-Lindau: diagnostic and management recommendations. Surgery 124:1153-1159
52.Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL. 2002 Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology 225:751-8
53.Cornish D, Pont A, Minor D, et al. 1984 Metastatic islet cell tumor in von Hippel-Lindau disease. Am J Med 77:147-150
54.Manski TJ, Heffner DK, Glenn GM, et al. 1997 Endolymphatic sac tumors: a source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277:1461-1465
55.Glasker S, Lonser RR, Tran MG, Ikejiri B, Butman JA, Zeng W, Maxwell PH, Zhuang Z, Oldfield EH, Vortmeyer AO. 2005 Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res 65:10847-53
56.Megerian CA, Haynes DS, Poe DS, et al. 2002 Hearing preservation surgery for small endolymphatic sac tumors in patients with von Hippel-Lindau syndrome. Otol Neurotol 23:378-387
57.Kim HJ, Butman JA, Brewer C, Zalewski C, Vortmeyer AO, Glenn G, Oldfield EH, Lonser RR. 2005 Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg 102:503-12
58.Kempermann G, Neumann HP, Volk B. 1998 Endolymphatic sac tumors. Histopathology 33:2-10
59.Latif F, Tory K, Gnarra J, et al. 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320
60.Kaelin WG Jr. 2002 Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-82
61.Stolle C, Glenn G, Zbar B, et al. 1998 Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423
62.Vortmeyer AO, Huang SC, Pack SD, Koch CA, et al. 2002 Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 21: 1167-1170
63.Kondo, K. & W.G. Kaelin. 2001 The von Hippel-Lindau tumor suppressor gene. Exp. Cell Res. 264: 117-125
64.Bender B.U., M. Gutsche, S. Glasker, et al. 2000 Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85: 4568-4574
65.Khosla S., V.M. Patel, I.D. Hay et al. 1991 Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 87: 1691-1699
66.Zeiger, M.A., B. Zbar, H. Keiser et al. 1995 Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer 13: 151-156
67.Gnarra J, Ward J, Porter F, et al. 1997 Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 94:9102-9107
68.Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K. 2002 New insights into the genetics of familial chromaffin cell tumors. Ann NY Acad Sci 970:11-28
69.Brauer VH, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA. 2004 RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70: should thyroidectomy be performed ? Endocr Practice 10 (1): 5-9
70.Vortmeyer AO, Huang SC, Koch CA, et al. 2000 Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res 60:5963-5965
71.Lee JY, Dong SM, Park WS, et al. 1998 Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58:504-508
72.Koch CA, Huang SC, Zhuang Z, et al. 2002 Somatic VHL gene deletion and point mutation in MEN 2-associated pheochromocytoma. Oncogene 21:479-482
73.Shuin T, Kondo K, Ashida S, et al. 1999 Germline and somatic mutations in the von Hippel-Lindau disease gene and its significance in the development of kidney cancer. Contrib Nephrol 128:1-10